Sen. Martin Hickey

Maddy summarySB 270 appropriates $500 million from the general fund to the New Mexico Department of Health for fiscal year 2026 to support the operations of federally qualified health centers (FQHCs). This funding directly affects FQHCs across the state, which provide primary care services in underserved communities. The bill establishes a one-time appropriation with unspent funds reverting to the general fund by the end of fiscal year 2026. It does not create new programs but allocates existing state resources to sustain current FQHC operations.

Maddy summarySB 477 prohibits health insurers in New Mexico from requiring prior authorization or step therapy (forcing patients to try cheaper drugs first) for specific prescription medications. It directly affects patients with autoimmune disorders, cancer, cholesterol issues, or substance use disorders, and those prescribed medications in three drug classes: GLP-1 agonists (used for diabetes/weight management), glucose-dependent insulinotropic polypeptide, and GLP-1 receptor agonists. Insurers may still require authorization only if a biosimilar, interchangeable biologic, or generic version of the drug is available. The bill aims to streamline access to these treatments by removing bureaucratic barriers, but it remains pending after being postponed indefinitely in June 2025.

Maddy summarySB 520 clarifies that dental and vision only health insurance plans are excluded from New Mexico's 3.75% health insurance premium surtax. This means insurance providers selling standalone dental or vision coverage will not pay the additional tax on premiums for these specific plans. The surtax continues to apply to most other health insurance plans, including those covering hospital and medical expenses. The change takes effect January 1, 2026, ensuring dental and vision plans remain tax-exempt under the state's health insurance tax code.

Maddy summarySB 295 creates tax deductions for healthcare providers on specific income streams. It allows deductions for sales of medical equipment/supplies/drugs, payments from patients for services not provided through insurance plans (like direct billing), and out-of-pocket patient payments (copayments/deductibles) excluding Medicaid services. The bill also removes an expiration date for existing copayment/deductible deductions and requires the state to reimburse healthcare providers for taxes paid on Medicaid reimbursements. These changes directly affect doctors, clinics, and other healthcare practitioners who bill patients or insurers, reducing their taxable income for qualifying services.

Maddy summarySB 443 prohibits health insurance plans in New Mexico from requiring patients to pay copays, deductibles, or coinsurance for cholesterol-lowering drugs. It applies to all group health coverage, individual health insurance policies, HMOs, and nonprofit health care plans delivered, issued, or renewed in the state. The bill defines "cost sharing" broadly to include any out-of-pocket payment beyond premiums, ensuring these medications are covered without financial barriers. The law would take effect on January 1, 2026, if enacted.

Maddy summarySenate Memorial 12 is a non-binding request asking the Legislative Finance Committee to study options for increasing pay for medical specialty providers in New Mexico. It cites challenges like low Medicaid reimbursement rates (60-70% of Medicare rates for procedures), high reliance on government insurance (only 25% of billing from commercial markets), and long patient wait times (6-18 months for specialists). The memorial specifically requests $200,000 to fund a contractor for the study, aiming to identify ways to make New Mexico competitive in recruiting and retaining these providers. This resolution does not change current pay rates but seeks to inform future legislative action on provider compensation.

Maddy summarySB 336 requires New Mexico's Medicaid Managed Care Organizations (MCOs) to assign a proportional number of Medicaid recipients across all contracted MCOs, including newly contracted ones. This directly affects Medicaid recipients (the people receiving the program) and the MCOs that provide their healthcare services. The key provision mandates that the state ensure Medicaid recipients are distributed fairly among all MCOs, preventing any single organization from serving a disproportionately high or low share of enrollees. The bill does not change Medicaid eligibility, benefits, or coverage requirements.

Maddy summarySB 367 would appropriate $350,000 from the state general fund to the University of New Mexico's Health Sciences Center for a Spanish-language medical curriculum. The funds would support curriculum development and implementation through the Health Sciences Center Office for Diversity, Equity and Inclusion, directly benefiting health sciences students preparing for healthcare roles in Spanish-speaking communities. The program would operate during fiscal years 2026 and 2027, with any unspent funds reverting to the general fund by year-end 2027. This bill focuses on enhancing language training for future healthcare providers without altering existing healthcare policies or regulations.

Maddy summarySB 176 sets new limits on recoverable damages in New Mexico medical malpractice cases, capping total non-punitive awards per injury based on provider type and year (e.g., $750,000 for hospitals in 2022, rising to $6 million by 2027 with annual inflation adjustments). It requires payments from the Patient Compensation Fund to be made as medical expenses occur, directs 75% of punitive damages to the state, and creates a Patient Safety Improvement Fund. The bill also limits attorney fees in malpractice claims and adjusts caps annually using the consumer price index. These changes directly affect patients filing malpractice suits, healthcare providers, and the state’s compensation and safety funding mechanisms.

Maddy summarySB 207 would expand New Mexico's insurance rules to exempt certain medications from prior authorization requirements. It directly affects patients with autoimmune disorders, cancer, rare diseases (affecting fewer than 200,000 people in the U.S.), or substance use disorders, and insurers covering their prescriptions. The bill requires insurers to cover these medications without prior approval or step therapy (trying cheaper drugs first) when a doctor deems them medically necessary for the condition. This change applies only when no cheaper generic, biosimilar, or interchangeable biologic alternative is available.